Detail page

Knowledge Web

Person

Marcus Unterrainer (1989-)

Arzt

Name	Marcus Unterrainer
Time	1989- (Date of birth and death)
Place	Penzberg (Geburtsort) Deutschland
Gender	männlich
Profession	Arzt (characteristic profession)
Further information	Dissertation, Medizinische Fakultät, Ludwig-Maximilians-Universität München, 2017. - 9Dissertation, Medizinische Fakultät, Ludwig-Maximilians-Universität München, 2019. - Habilitationsschrift, Medizinische Fakultät, Ludwig-Maximilians-Universität München, 2020
Record type	Person
GND-Identifier	1196848491
Record ID	1196848491
Involved in show all PSMA-PET/CT response after metastasis-directed radiotherapy of bone oligometastases in prostate cancer [68Ga]Ga-FAPI-46 PET/CT for penile cancer – a feasibility study [68 Ga]Ga-FAPI-46 PET/CT for locoregional lymph node staging in urothelial carcinoma of the bladder prior to cystectomy: initial experiences from a pilot analysis Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [18F]SiTATE Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment Aktuelle nuklearmedizinische Entwicklungen beim fortgeschrittenen Nierenzellkarzinom Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy TSPO PET signal using [18F]GE180 is associated with survival in recurrent gliomas 68Ga-EMP-100 PET/CT—a novel method for non-invasive assessment of c-MET expression in non-small cell lung cancer Combination of pre-treatment dynamic [18F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy—a multicenter retrospective analysis Acetyl-dl-leucine in cerebellar ataxia ([18F]-FDG-PET study): how does a cerebellar disorder influence cortical sensorimotor networks? Increased TSPO PET signal after radiochemotherapy in IDH-wildtype glioma—indicator for treatment-induced immune activation? Feasibility of [68Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma 18F-FET PET radiomics-based survival prediction in glioblastoma patients receiving radio(chemo)therapy Can Radiomics Provide Additional Information in [F-18]FET-Negative Gliomas? Imaging standardisation in metastatic colorectal cancer: A joint EORTC-ESOI-ESGAR expert consensus recommendation L-type amino acid transporter (LAT) 1 expression in 18F-FET-negative gliomas 68Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F]FET PET radiomics Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions The diagnostic challenge of coexistent sarcoidosis and thyroid cancer – a retrospective study TERT-Promoter Mutational Status in Glioblastoma – Is There an Association With Amino Acid Uptake on Dynamic 18F-FET PET? Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC Transformation of diffuse large B cell lymphoma into dendritic sarcoma under CAR T cell therapy detected on 18F-FDG PET/CT Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma Longitudinal TSPO expression in tau transgenic P301S mice predicts increased tau accumulation and deteriorated spatial learning Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury Die molekulare Bildgebung primärer und sekundärer Hirntumoren mittels dynamischer O-(2-18F-Fluorethyl)-L-Tyrosin Positronenemissionstomographie (18F-FET PET) Recent advances of PET imaging in clinical radiation oncology Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic 18F-FET PET Long-term outcome of rare oncocytic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy In response to: The validity of 18F-GE180 as a TSPO imaging agent Evaluation der TSPO-Expression bei schubförmig-remittierender multipler Sklerose und high-grade Gliomen mittels [18F]GE-180 Positronen-Emissions-Tomographie Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation Comparison of 18F-GE-180 and dynamic 18F-FET PET in high grade glioma: a double-tracer pilot study Voxel-wise analysis of dynamic 18F-FET PET: a novel approach for non-invasive glioma characterisation 18F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing–remitting multiple sclerosis Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent TauPET Imaging? Data on specificity of [F-18]GE180 uptake for TSPO expression in rodent brain and myocardium TSPO imaging using the novel PET ligand [18F]GE-180: quantification approaches in patients with multiple sclerosis Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET Towards standardization of 18F-FET PET imaging: do we need a consistent method of background activity assessment? 18F-FET PET prior to recurrent high-grade glioma re-irradiation—additional prognostic value of dynamic time-to-peak analysis and early static summation images? In Vivo Imaging of Glial Activation after Unilateral Labyrinthectomy in the Rat: A [F-18]GE180-PET study Suspected recurrence of brain metastases after focused high dose radiotherapy: can [18F]FET- PET overcome diagnostic uncertainties? Implementation of the European multicentre database of healthy controls for [123I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Marcus Unterrainer (1989-)

PSMA-PET/CT response after metastasis-directed radiotherapy of bone oligometastases in prostate cancer

[68Ga]Ga-FAPI-46 PET/CT for penile cancer – a feasibility study

[68 Ga]Ga-FAPI-46 PET/CT for locoregional lymph node staging in urothelial carcinoma of the bladder prior to cystectomy: initial experiences from a pilot analysis

Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy

Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [18F]SiTATE

Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial

Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE

Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors

Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment

Aktuelle nuklearmedizinische Entwicklungen beim fortgeschrittenen Nierenzellkarzinom

Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy

Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy

TSPO PET signal using [18F]GE180 is associated with survival in recurrent gliomas

68Ga-EMP-100 PET/CT—a novel method for non-invasive assessment of c-MET expression in non-small cell lung cancer

Combination of pre-treatment dynamic [18F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma

The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy—a multicenter retrospective analysis

Acetyl-dl-leucine in cerebellar ataxia ([18F]-FDG-PET study): how does a cerebellar disorder influence cortical sensorimotor networks?

Increased TSPO PET signal after radiochemotherapy in IDH-wildtype glioma—indicator for treatment-induced immune activation?

Feasibility of [68Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma

18F-FET PET radiomics-based survival prediction in glioblastoma patients receiving radio(chemo)therapy

Can Radiomics Provide Additional Information in [F-18]FET-Negative Gliomas?

Imaging standardisation in metastatic colorectal cancer: A joint EORTC-ESOI-ESGAR expert consensus recommendation

L-type amino acid transporter (LAT) 1 expression in 18F-FET-negative gliomas

68Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results

Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition

Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy

Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F]FET PET radiomics

Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours

PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions

The diagnostic challenge of coexistent sarcoidosis and thyroid cancer – a retrospective study

TERT-Promoter Mutational Status in Glioblastoma – Is There an Association With Amino Acid Uptake on Dynamic 18F-FET PET?

Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC

Transformation of diffuse large B cell lymphoma into dendritic sarcoma under CAR T cell therapy detected on 18F-FDG PET/CT

Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma

Longitudinal TSPO expression in tau transgenic P301S mice predicts increased tau accumulation and deteriorated spatial learning

Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury

Die molekulare Bildgebung primärer und sekundärer Hirntumoren mittels dynamischer O-(2-18F-Fluorethyl)-L-Tyrosin Positronenemissionstomographie (18F-FET PET)

Recent advances of PET imaging in clinical radiation oncology

Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic 18F-FET PET

Long-term outcome of rare oncocytic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy

In response to: The validity of 18F-GE180 as a TSPO imaging agent

Evaluation der TSPO-Expression bei schubförmig-remittierender multipler Sklerose und high-grade Gliomen mittels [18F]GE-180 Positronen-Emissions-Tomographie

Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation

Comparison of 18F-GE-180 and dynamic 18F-FET PET in high grade glioma: a double-tracer pilot study

Voxel-wise analysis of dynamic 18F-FET PET: a novel approach for non-invasive glioma characterisation

18F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy

TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing–remitting multiple sclerosis

Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent TauPET Imaging?

Data on specificity of [F-18]GE180 uptake for TSPO expression in rodent brain and myocardium

TSPO imaging using the novel PET ligand [18F]GE-180: quantification approaches in patients with multiple sclerosis

Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET

Towards standardization of 18F-FET PET imaging: do we need a consistent method of background activity assessment?

18F-FET PET prior to recurrent high-grade glioma re-irradiation—additional prognostic value of dynamic time-to-peak analysis and early static summation images?

In Vivo Imaging of Glial Activation after Unilateral Labyrinthectomy in the Rat: A [F-18]GE180-PET study

Suspected recurrence of brain metastases after focused high dose radiotherapy: can [18F]FET- PET overcome diagnostic uncertainties?

Implementation of the European multicentre database of healthy controls for [123I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes

Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls